Companies:
53,102
Total Market Cap:
170178583942205.13
Global Rank
#1483
Country Rank
#38
Market Cap
16.08 B
Price
38.07
Change (%)
2.38%
Volume
1.93 M
PharmaEssentia's latest marketcap:
16.08 B
As of 07/17/2026, PharmaEssentia's market capitalization has reached $16.08 B. According to our data, PharmaEssentia is the 1483th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 16.08 B |
| Revenue (ttm) | 541.56 M |
| Net Income (ttm) | 183.56 M |
| Shares Out | 412.24 M |
| EPS (ttm) | 0.45 |
| Forward PE | 46.36 |
| Ex-Dividend Date | 07/09/2026 |
| Earnings Date | 08/12/2026 |
Market Cap Chart
Data Updated: 07/17/2026
PharmaEssentia's yearly market capitalization.
PharmaEssentia has seen its market value grow from NT$25.59 B to NT$519.42 B since 2014, representing a total increase of 1,929.49% and an annual compound growth rate (CAGR) of 29.80%.
| Date | Market Cap(NT$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/17/2026 | NT$519.42 B | $16.08 B | 103.53% | 1483 |
| 12/31/2025 | NT$173.83 B | $5.54 B | -15.09% | 2744 |
| 12/31/2024 | NT$204.73 B | $6.23 B | 78.68% | 2514 |
| 12/29/2023 | NT$114.58 B | $3.73 B | -20.34% | 3626 |
| 12/30/2022 | NT$143.84 B | $4.7 B | 84.26% | 2835 |
| 12/30/2021 | NT$78.07 B | $2.82 B | 215.94% | 4962 |
| 12/31/2020 | NT$24.71 B | $0 | 2.44% | 8582 |
| 12/31/2019 | NT$24.12 B | $805.14 M | -36.91% | 7770 |
| 12/28/2018 | NT$38.23 B | $1.25 B | 22.23% | 5403 |
| 12/29/2017 | NT$31.28 B | $1.05 B | -11.35% | 6901 |
Company Profile
About PharmaEssentia Corporation
PharmaEssentia Corporation is a biopharmaceutical company dedicated to developing treatments for human diseases, operating in Taiwan and internationally.
Key Products and Treatments
- Ropeginterferon alfa-2b: Used for treating chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia.
- Oncology Therapies: Includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies for solid tumors.
- P1101 + anti PD-1: A treatment for hepatocellular carcinoma.
- PEG-GCSF: Developed for neutropenia treatment.
Research Focus Areas
The company specializes in drug research and development programs, with a focus on:
- Hematology
- Infectious Disease
- Oncology
Company Background
Founded in 1990, PharmaEssentia Corporation is headquartered in Taipei, Taiwan.
Frequently Asked Questions
-
What is PharmaEssentia's (TPE-6446) current market cap?As of 07/17/2026, PharmaEssentia (including the parent company, if applicable) has an estimated market capitalization of $16.08 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does PharmaEssentia (TPE-6446) rank globally by market cap?PharmaEssentia global market capitalization ranking is approximately 1483 as of 07/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.